223 related articles for article (PubMed ID: 35815468)
1. Gender-Affirming Hormone Pharmacokinetics Among Adolescent and Young Adult Transgender Persons Receiving Daily Emtricitabine/Tenofovir Disoproxil Fumarate.
Yager J; Brooks KM; Brothers J; Mulligan K; Landovitz RJ; Reirden D; Malhotra M; Glenny C; Harding P; Powell T; Anderson PL; Hosek S
AIDS Res Hum Retroviruses; 2022 Dec; 38(12):939-943. PubMed ID: 35815468
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of Emtricitabine/Tenofovir Disoproxil Fumarate Among Transgender Adolescents and Young Adults Without HIV Receiving Gender Affirming Hormones.
Yager J; Brooks KM; Brothers J; Mulligan K; Landovitz R; Reirden D; Glenny C; Malhotra M; Anderson PL; Hosek S
AIDS Res Hum Retroviruses; 2022 Nov; 38(11):840-846. PubMed ID: 35943868
[TBL] [Abstract][Full Text] [Related]
3. Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men.
Shieh E; Marzinke MA; Fuchs EJ; Hamlin A; Bakshi R; Aung W; Breakey J; Poteat T; Brown T; Bumpus NN; Hendrix CW
J Int AIDS Soc; 2019 Nov; 22(11):e25405. PubMed ID: 31692269
[TBL] [Abstract][Full Text] [Related]
4. Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy.
Cirrincione LR; Podany AT; Havens JP; Bares SH; Dyavar SR; Gwon Y; Johnson TM; Amoura NJ; Fletcher CV; Scarsi KK
J Antimicrob Chemother; 2020 May; 75(5):1242-1249. PubMed ID: 32065631
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy.
Yager JL; Anderson PL
Expert Opin Drug Metab Toxicol; 2020 Jun; 16(6):463-474. PubMed ID: 32250177
[TBL] [Abstract][Full Text] [Related]
6. Impact of feminizing hormone therapy on tenofovir and emtricitabine plasma pharmacokinetics: a nested drug-drug interaction study in a cohort of Brazilian transgender women using HIV pre-exposure prophylaxis.
Cattani VB; Jalil EM; Eksterman L; Torres T; Cardoso SW; Castro CRV; Monteiro L; Wilson E; Bushman L; Anderson P; Veloso VG; Grinsztejn B; Estrela R;
J Antimicrob Chemother; 2022 Sep; 77(10):2729-2736. PubMed ID: 35815666
[TBL] [Abstract][Full Text] [Related]
7. Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study.
Grant RM; Pellegrini M; Defechereux PA; Anderson PL; Yu M; Glidden DV; O'Neal J; Yager J; Bhasin S; Sevelius J; Deutsch MB
Clin Infect Dis; 2021 Oct; 73(7):e2117-e2123. PubMed ID: 32766890
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial.
Marzinke MA; Hanscom B; Wang Z; Safren SA; Psaros C; Donnell D; Richardson PA; Sullivan P; Eshleman SH; Jennings A; Feliciano KG; Jalil E; Coutinho C; Cardozo N; Maia B; Khan T; Singh Y; Middelkoop K; Franks J; Valencia J; Sanchez N; Lucas J; Rooney JF; Rinehart AR; Ford S; Adeyeye A; Cohen MS; McCauley M; Landovitz RJ; Grinsztejn B;
Lancet HIV; 2023 Nov; 10(11):e703-e712. PubMed ID: 37783219
[TBL] [Abstract][Full Text] [Related]
9. Kidney function and daily emtricitabine/tenofovir disoproxil fumarate pre-exposure prophylaxis against HIV: results from the real-life multicentric demonstrative project PrEP Brazil.
Petruccelli KCS; Baía-da-Silva DC; Val F; Valões MS; Cubas-Vega N; Silva-Neto AV; Sampaio V; Alencar A; Pecoits-Filho R; Moreira RC; Cardoso SW; Moreira RI; Leite IC; Madruga JV; Kallas EG; Alencastro PR; Hoagland B; Grinsztejn B; Santos VGV; Lacerda MVG
AIDS Res Ther; 2022 Feb; 19(1):12. PubMed ID: 35209929
[TBL] [Abstract][Full Text] [Related]
10. Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study.
Hiransuthikul A; Janamnuaysook R; Himmad K; Kerr SJ; Thammajaruk N; Pankam T; Phanjaroen K; Mills S; Vannakit R; Phanuphak P; Phanuphak N;
J Int AIDS Soc; 2019 Jul; 22(7):e25338. PubMed ID: 31298497
[TBL] [Abstract][Full Text] [Related]
11. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Mayer KH; Molina JM; Thompson MA; Anderson PL; Mounzer KC; De Wet JJ; DeJesus E; Jessen H; Grant RM; Ruane PJ; Wong P; Ebrahimi R; Zhong L; Mathias A; Callebaut C; Collins SE; Das M; McCallister S; Brainard DM; Brinson C; Clarke A; Coll P; Post FA; Hare CB
Lancet; 2020 Jul; 396(10246):239-254. PubMed ID: 32711800
[TBL] [Abstract][Full Text] [Related]
12. Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial.
Glidden DV; Das M; Dunn DT; Ebrahimi R; Zhao Y; Stirrup OT; Baeten JM; Anderson PL
J Int AIDS Soc; 2021 May; 24(5):e25744. PubMed ID: 34021709
[TBL] [Abstract][Full Text] [Related]
13. Gender Affirming Hormones Do Not Affect the Exposure and Efficacy of F/TDF or F/TAF for HIV Preexposure Prophylaxis: A Subgroup Analysis from the DISCOVER Trial.
Cespedes MS; Das M; Yager J; Prins M; Krznaric I; de Jong J; Xiao D; Shao Y; Wong P; Kintu A; Carter C; Hoornenborg E; Ruane P; Phoenix J; Younis I; Halperin J
Transgend Health; 2024 Feb; 9(1):46-52. PubMed ID: 38312459
[TBL] [Abstract][Full Text] [Related]
14. Changes in kidney function among men having sex with men starting on demand tenofovir disoproxil fumarate - emtricitabine for HIV pre-exposure prophylaxis.
Liegeon G; Antoni G; Pialoux G; Capitant C; Cotte L; Charreau I; Tremblay C; Cua E; Senneville E; Raffi F; Meyer L; Molina JM;
J Int AIDS Soc; 2020 Feb; 23(2):e25420. PubMed ID: 32086878
[TBL] [Abstract][Full Text] [Related]
15. Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.
Walensky RP; Horn T; McCann NC; Freedberg KA; Paltiel AD
Ann Intern Med; 2020 May; 172(9):583-590. PubMed ID: 32150602
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women.
Tanaudommongkon A; Chaturvedula A; Hendrix CW; Fuchs EJ; Shieh E; Bakshi RP; Marzinke MA
Br J Clin Pharmacol; 2022 Aug; 88(8):3674-3682. PubMed ID: 35285974
[TBL] [Abstract][Full Text] [Related]
17. Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project.
Tang EC; Vittinghoff E; Anderson PL; Cohen SE; Doblecki-Lewis S; Bacon O; Coleman ME; Buchbinder SP; Chege W; Kolber MA; Elion R; Shlipak M; Liu AY
J Acquir Immune Defic Syndr; 2018 Feb; 77(2):193-198. PubMed ID: 28991887
[TBL] [Abstract][Full Text] [Related]
18. Estradiol and Spironolactone Plasma Pharmacokinetics Among Brazilian Transgender Women Using HIV Pre-Exposure Prophylaxis: Analysis of Potential Interactions.
Cattani VB; Jalil EM; Eksterman L; Torres T; Wagner Cardoso S; Castro CRV; Monteiro L; Wilson E; Bushman L; Anderson P; Veloso VG; Grinsztejn B; Estrela R;
Clin Pharmacokinet; 2023 Jul; 62(7):1031-1041. PubMed ID: 37261664
[TBL] [Abstract][Full Text] [Related]
19. Method of Calculating Renal Function Estimates Could Inappropriately Exclude Transgender Patients Receiving Gender-Affirming Hormone Therapy from Pre-Exposure Prophylaxis Eligibility.
Patel N; Blumenthal J; Dubé MP; Hood A; Bolan R; Morris S
LGBT Health; 2022 Apr; 9(3):199-206. PubMed ID: 35196473
[No Abstract] [Full Text] [Related]
20. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
Mugwanya KK; Wyatt C; Celum C; Donnell D; Mugo NR; Tappero J; Kiarie J; Ronald A; Baeten JM;
JAMA Intern Med; 2015 Feb; 175(2):246-54. PubMed ID: 25531343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
